By james art The collaboration will expand access to highly sensitive NULISA immunoassays for clinical biomarker analysis.
GHENT, Belgium and FREMONT, Calif.–( BUSINESS WIRE )–#IVD–ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in the development of biomarkers for neurodegenerative diseases, and Alamar Biosciences, a leader in ultrasensitive immunoassay technologies, today announced a partnership in the development of customized biomarker analysis solutions using Alamar’s NULISA™ (Nucleic Acid Linked Immuno-Sandwich Assay) immunoassay platform and the ARGO™ HT System. This collaboration aims to provide advanced tools for the discovery and quantification of critical biomarkers to support the therapeutic development of neurological diseases.
Under the terms of the partnership, Alamar Biosciences and ADx NeuroSciences will combine their respective expertise to provide customized assay solutions to meet the specific needs of pharmaceutical companies developing new therapies for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS.
“We are thrilled to partner with ADx NeuroSciences, a recognized leader in neurodegenerative biomarker research,” said Dr. Yuling Luo, Chairman and CEO of Alamar Biosciences. “By combining the ultra-sensitive detection capabilities of our NULISA platform with ADx’s extensive expertise in neuroscience antibody development and assays, we aim to accelerate the development of biomarker assays that can facilitate the development and approval of disease-modifying therapies for neurodegenerative diseases .”
Koen Dewaele, CEO of ADx NeuroSciences, commented, “Our collaboration with Alamar Biosciences marks a significant step forward in our mission to support pharmaceutical companies advancing their therapeutic programs. Each phase in the search for a therapeutic, from preclinical work to the launch of the best drug, requires specific biomarker tools. By working with different technology platforms, we are able to make our biomarker assays available to the right technology at the right time. By adding the NULISA platform with its remarkable sensitivity to our range of possible platforms, it strengthens our ability to support our pharma network in their search for tailor-made biomarkers.”
This strategic collaboration underscores both companies’ commitment to advancing biomarker discovery and expanding opportunities for early diagnosis and treatment of neurodegenerative diseases. Leveraging the power of the NULISA platform, Alamar Biosciences and ADx NeuroSciences aim to deliver cutting-edge solutions that will benefit clinical research and help develop new therapeutics.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s patented NULISA platform together with the ARGO™ HT system works seamlessly with the latest advances in genomics to achieve single-digit atomic detection sensitivity, significantly surpassing high-sensitivity protein detection technologies on the market today. For more information, please visit alamarbio.com.
About ADx NeuroSciences NV
ADx NeuroSciences specializes in the research and development of neurodegenerative biomarker tools for diseases such as Alzheimer’s and Parkinson’s. His expertise is used by pharmaceutical and diagnostic companies around the world for the concept, development, production and global commercialization of new biomarkers supporting the development of promising drugs, either by monitoring the effect of a drug or by selecting the right patients at a very early stage. stage stage of the disease. These tests can be applied to a variety of platforms from research to IVD use. The company was founded in 2011 and was acquired in 2022 by Fujirebio, a member of HU Group Holdings Inc., which is listed on the Tokyo Stock Exchange (TSE: 4544). For more information, please visit www.adxneurosciences.com.
About Fujirebio
Fujirebio, a member of HU Group Holdings Inc., is a global leader in high-quality IVD testing with more than 50 years of experience in the concept, development, manufacture and worldwide commercialization of robust IVD products. Fujirebio was the first company to develop and market CSF biomarkers for AD testing under the Innogenetics brand more than 25 years ago. Fujirebio remains the only company with such a comprehensive range of manual and fully automated neurodegenerative disease assays, and has consistently partnered with organizations and clinical experts worldwide to develop new pathways for earlier, easier, and more complete neurodegenerative disease tools. diagnostics. For more information, please visit www.fujirebio.com.
Contacts
For media inquiries please contact:
Alamar Biosciences, Inc. Media contact:
April Falcone
Alamar Biosciences
[email protected]
(510) 838-1783
ADx NeuroSciences NV:
Anne De Vos
ADx NeuroSciences
[email protected]
+32 9 329 1486